問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

Division of General Internal Medicine

Division of Hematology & Oncology

更新時間：2024-02-21

邱玲榕
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

34Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

邱玲榕

List

39Cases

2023-08-01 - 2029-06-30

Phase III

Active
A Phase 3, Randomized, Open Label Study Evaluating the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Versus Standard of Care Therapy in Participants With Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma (OLYMPIA-4)

  • Condition/Disease

    B-Cell Non-Hodgkin Lymphoma (B-NHL)

  • Test Drug

    Odronextamab (REGN1979)

Participate Sites
11Sites

Not yet recruiting8Sites

Recruiting2Sites

2023-06-01 - 2028-11-27

Phase III

Active
A Phase 3, Open label, Randomized Study Comparing the Efficacy and Safety of Odronex tamab (REGN1979), an anti-CD20 × anti- CD3 bispecific antibody, in Combination with CHOP (Odro-CHOP) versus Rituximab in combination with CHOP (R-CHOP) in Previously Untreated Participants with Diffuse Large Bcell Lymphoma (DLBCL) (OLYMPIA-3)

  • Condition/Disease

    Previously Untreated Participants with Diffuse Large Bcell Lymphoma (DLBCL)

  • Test Drug

    injection

Participate Sites
9Sites

Recruiting9Sites

2024-12-30 - 2031-06-26

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2022-09-01 - 2026-12-31

Phase III

Active
A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2

  • Condition/Disease

    Relapsed or Refractory Multiple Myeloma

  • Test Drug

    CC-92480 (BMS-986348)

Participate Sites
7Sites

Recruiting7Sites

2024-03-01 - 2030-07-16

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2024-07-01 - 2029-09-19

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2020-04-01 - 2032-06-30

Others

Active
A Phase 1b/3 double-blind, randomized, active-controlled, 3-stage, biomarker adaptive study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractory follicular lymphoma

  • Condition/Disease

    relapsed/refractory follicular lymphoma

  • Test Drug

    Tazemetostat

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2021-11-01 - 2030-12-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2023-06-01 - 2028-11-27

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB